论文部分内容阅读
阿必鲁泰皮下注射剂是一种长效胰高血糖素样肽-1(GLP-1)受体激动剂,每周皮下注射1次,主要结合饮食与运动用于改善2型糖尿病患者的血糖控制,欧洲药物管理局和美国食品药品监督管理局分别于2014年3月26日和4月15日批准其上市。相比安慰剂,阿必鲁泰在控制血糖,减少糖基化血红蛋白、空腹血糖、餐后血糖波动以及减肥等方面都有显著作用,且长期稳定性和安全性较好,已成为治疗2型糖尿病的一种新选择。本文对其药理作用、临床研究及安全性等做一综述。
Aphrodite Hypodermic Injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist injected subcutaneously once weekly to improve glycemic control in patients with type 2 diabetes, primarily in combination with diet and exercise Control, the European Medicines Agency and the U.S. Food and Drug Administration approved their listing on March 26, 2014 and April 15, respectively. Compared with placebo, Albizin has a significant effect in controlling blood glucose, reducing glycosylated hemoglobin, fasting blood glucose, postprandial blood glucose fluctuations and weight loss, and long-term stability and safety, has become the treatment of type 2 A new option for diabetes. This article reviews its pharmacological effects, clinical studies and safety.